Purification of glucagon-like peptide 1 analogs

Inactive Publication Date: 2020-11-26
BACHEM HOLDING
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides methods for effectively purifying glucagon-like peptides, particularly GLP-1 analogs such as Liraglutide, at an industrial or laboratory scale. The methods involve a two-dimensional reversed phase high performance liquid chromatography protocol using specific mobile phases and pH values. The invention also includes a method for purifying GLP-1 using a combination of RP-HPLC and aqueous mobile phases. The purification of glucagon-like peptides can be challenging due to their propensity to aggregate, but the present invention provides methods that improve the yield and purity of the final product.

Problems solved by technology

As a result, the purification of the final product may very challenging.
Purification of glucagon-like peptides is particularly demanding due to their propensity to aggregate.
Therefore, the purity is not as high as desired and the peptide is obtained in a basic buffer which may have drawbacks for the storage of the peptide, in particular as the basic buffer agents used in WO 2011 / 161007 are not evaporable.
This method is rather complex.
Moreover, the use of two different stationary phases is not economical.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Purification of glucagon-like peptide 1 analogs
  • Purification of glucagon-like peptide 1 analogs
  • Purification of glucagon-like peptide 1 analogs

Examples

Experimental program
Comparison scheme
Effect test

example 1

tion of Purification Conditions

[0162]Small scale experiments were carried out to identify suitable purification conditions. The seven mobile phase buffers given in column 2 of Table 2 were tested each on four different stationary phases as indicated in line 1, columns 3-6 of Table 2. Each mobile phase buffer was used to prepare a Buffer A consisting of 3% (v / v) acetonitrile in an aqueous solution of said buffer, and a Buffer B consisting of 67 or 80% (v / v) acetonitrile in an aqueous solution of said buffer. The buffer concentrations in the aqueous solutions were between 20 and 400 mM, depending on the nature of the mobile phase buffer.

[0163]Each line of Table 2 represents four different one dimensional RP-HPLC runs, namely one run for each of the four stationary phases tested. For each of said runs, the Buffers A and B prepared with the mobile phase buffer indicated in column 2 the respective line were used. The following general protocol applied: Crude Liraglutide peptide produced ...

example 2

sional RP-HPLC Purification

[0167]The purification involved a chromatographic purification at pH 7.5 in the first dimension, followed by a chromatographic purification under acidic conditions in the second dimension.

[0168]A 5 cm MODcol column (Grace) packed with C8-bonded silica (approx. bed-depth 32 cm) was used on a preparative HPLC system (Knauer HPLC pump 1800) with detection at 220 nm (Knauer smartline UV detector 2500) and an automated fraction collector (Büchi C-660). The same stationary phase was used in both dimensions of the purification protocol. Crude Liraglutide produced by Fmoc SPPS (purity>60%) was used as a starting material. The sample was loaded on the column at a flow rate of 90 ml / min. The detailed elution protocols for each step are given in Tables 3 and 4 below. The buffer concentration in the aqueous part of the mobile phase used in the first dimension was 20 mM.

TABLE 3Parameters first purification dimensionSample loading bufferaqueous ammonium phosphate pH 7.5...

example 3

sional RP-HPLC Purification

[0171]The purification involved a chromatographic purification at pH 7.7 in the first dimension, followed by a chromatographic purification under acidic conditions in the second dimension.

[0172]A 5 cm MODcol column (Grace) packed with C8-bonded silica (approx. bed-depth 32 cm) was used on a preparative HPLC system (Knauer HPLC pump 1800) with detection at 220 nm (Knauer smartline UV detector 2500) and an automated fraction collector (Büchi C-660). The same stationary phase was used in both dimensions of the purification protocol. Crude Liraglutide produced by Fmoc SPPS was used as a starting material. The sample was loaded on the column at a flow rate of 43 ml / min (1st dimension) or 64 ml / min (2nd dimension). The detailed elution protocols for each step are given in Tables 5 and 6 below.

TABLE 5Parameters first purification dimensionSample loading bufferaqueous ammonium phosphate pH 7.7Buffer A3% (m / m) acetonitrile, aqueousammonium phosphate pH 7.7Buffer B6...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The present invention refers to a method of purifying a glucagon-like peptide 1 analogs, the method comprising a two dimensional reversed phase high performance liquid chromatography protocol, wherein the first step is carried out at a pH value between 7.0 to 7.8 using a mobile phase comprising a phosphate buffer and acetonitrile, and the second step is carried out at a pH value below 3.0 using a mobile phase comprising trifluoroacetic acid and acetonitrile.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional application of U.S. application Ser. No. 16 / 086,470, filed on Sep. 19, 2018, which is a 371 application of International Application No. PCT / EP2017 / 056668, filed on Mar. 21, 2017, which claims priority to EP. Application No. 16162066.1, filed on Mar. 23, 2016, each of which is incorporated herein by reference.SEQUENCE LISTING[0002]The Sequence Listing submitted herewith is an ASCII text file (2020-06-05_Sequence_Listing.text, created on Jun. 5, 2020, 3099 bytes) via EFS-Web is hereby incorporated by reference.FIELD OF THE INVENTION[0003]The present invention generally relates to the field of peptide purification at an industrial or laboratory scale. The present invention is directed to methods of effectively purifying glucagon-like peptide 1 analogs, such as Liraglutide.BACKGROUND OF THE INVENTION[0004]In preferred embodiments, the present invention refers to a method of purifying glucagon-like peptide 1 a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/02C07K14/605B01D15/32B01D15/18C07K2/00C07K14/47
CPCC07K14/4705C07K14/605C07K2/00G01N2030/027B01D15/1864G01N30/02B01D15/34B01D15/325G01N2030/065G01N2030/0065
InventorSTADELMAIER, ANDREASSCHOENLEBER, RALPH O.SAMSON, DANIELDETTNER, FRANK
OwnerBACHEM HOLDING